Skip to main content
SpringerLink
Log in

Pharmakokinetik der Neuroleptika

  • Chapter
Book cover Thioxanthene

Zusammenfassung

Die interindividuelle Ansprechbarkeit auf eine neuroleptische Therapie unterliegt einer beträchtlichen Variation. Im Prinzip kommen dafür 3 Hauptursachen in Betracht: 1. pharmakokinetische Unterschiede, die zu deutlich verschiedenen Neuroleptikakonzentrationen bei Patienten führen, die mit gleicher Dosierung behandelt werden; 2. unterschiedliche Dosis-Wirkungs-Beziehungen auf Rezeptorebene, die auf genetische oder andere krankheitsbezogene Faktoren zurückgeführt werden können; 3. Unterschiede in der Patientencompliance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aaes-Jorgensen T, Kirk L, Petersen E, Danneskiold-Samsoe P, Jorgensen A (1983) Serum con-centrations of the isomers of clopenthixol and a metabolite in patients given cis(Z)-clopenthixol decanoate in viscoleo. Psychopharmacology 81: 68–72

    Article  PubMed  CAS  Google Scholar 

  • Amdur MA (1979) Medication compliance in outpatient psychotherapy. Compr Psychiatry 20: 339–346

    Article  PubMed  CAS  Google Scholar 

  • Aravagiri M, Hawes EM, Midha KK (1984) Radioimmunoassay for the sulfoxide metabolite of trifluoperazine and its application to a kinetic study in humans. J Pharm Sci 73: 1383–1387

    Article  PubMed  CAS  Google Scholar 

  • Benitez J, Pinjas B, Garcia MA, Martinez C, Llerena A, Cobaleda J (1989) Debrisoquine oxidation phenotype in psychiatric patients. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. From molecular studies to clinical reality. Springer, Berlin Heidelberg New York London Paris Tokyo Hongkong (Pharmacology series, vol 7 ), pp 206–216

    Google Scholar 

  • Bressolle F, Bres J, Blanchin MD, Gomeni R (1984) Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. J Pharm Sci 73: 1128–1136

    Article  PubMed  CAS  Google Scholar 

  • Dahl SG (1976) Pharmacokinetics of methotrimeprazine after single and multiple doses. Clin Pharmacol Ther 19: 435–442

    PubMed  CAS  Google Scholar 

  • Dahl SG (1981) Pharmacokinetic aspects of new antipsychotic drugs. Neuropharmacology 20: 1299–1302

    PubMed  CAS  Google Scholar 

  • Dahl SG (1986) Plasma level monitoring of antipsychotic drugs clinical utility. Clin Pharmacokinet 11: 36–61

    Article  PubMed  CAS  Google Scholar 

  • Dahl SG, Strandjord RE (1977) Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21: 437–448

    PubMed  CAS  Google Scholar 

  • Dahl SG, Strandjord RE, Sigfusson S (1977) Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup. Eur J Clin Pharmacol 11: 305–310

    Article  PubMed  CAS  Google Scholar 

  • Dahl SG, Johnsen H, Lee CR (1982 a) Gas chromatographic mass spectrometric identification of O-demethylated and monohydroxylated metabolites of levomepromazine in blood from psychiatric patients by selected ion recording with high resolution. Biomed Mass Spectrom 9: 534–538

    Google Scholar 

  • Dahl SG, Bratlid T, Lingjaerde O (1982 b) Plasma and erythrocyte levels of methotrimeprazine and two of its nonpolar metabolites in psychiatric patients. Ther Drug Monit 4: 81–87

    Google Scholar 

  • Dahl SG, Kauffmann E, Mompon B, Purcell T (1987) Nuclear magnetic resonance analysis of methotrimeprazine (levomepromazine) hydroxylation in humans. J Pharm Sci 76: 541–544

    Article  PubMed  CAS  Google Scholar 

  • Farde L, Wiesel F-A, Nilsson L, Sedvall G (1989) The potential of positron emission tomography for pharmacokinetic and pharmacodynamic studies of neuroleptics. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. From molecular studies to clinical reality. Springer, Berlin Heidelberg New York London Paris Tokyo Hong Kong (Psychopharmacology series, vol 7 ), pp 32–39

    Google Scholar 

  • Gravem A, Engstrand E, Guleng RJ (1978) Cis(z)-clopenthixol and clopenthixol ( Sordinol) in chronic psychotic patients. Acta Psychiatr Scand 58: 384–388

    Google Scholar 

  • Hals P-A, Hall H, Dahl SG (1986) Phenothiazine drug metabolites: Dopamine D2 receptor, α1- and α2-adrenoceptor binding. Eur J Pharmacol 125: 373–381

    Article  PubMed  CAS  Google Scholar 

  • Hals P-A, Hall H, Dahl SG (1988) Muscarinic cholinergic and histamine HI reeptor binding of phenothiazine drug metabolites. Life Sci 43: 405–412

    Article  PubMed  CAS  Google Scholar 

  • Hulka BS, Cassel JC, Kupper LL (1976) Disparities between medications prescribed and consumed among chronic disease patients. In: Lasagna L (ed) Patient compliance. Futura, Mount Kisco, NY, pp 123–152

    Google Scholar 

  • Johnsen H, Dahl SG (1982) Identification of O-demethylated and ring-hydroxylated metabolites of methotrimeprazine (levomepromazine) in man. Drug Metab Dispos 10: 63–67

    PubMed  CAS  Google Scholar 

  • Jorgensen A (1980) Pharmacokinetic studies in volunteers of intravenous and oral cis(Z)- flupentixol and intramuscular cis(Z)-flupentixol decanoate in viscoleo. Eur J Clin Pharmacol 18: 355–360

    Article  PubMed  CAS  Google Scholar 

  • Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridges JW, Chasseaud LF (eds) Progress in drug metabolism, vol 9. Taylor & Francis, London, pp 111–174

    Google Scholar 

  • Jorgensen A, Aaes-Jorgensen T (1988) Pharmacokinetic variations of zuclopenthixol and flupentixol administered orally or intramuscularly as retard or depot formulations. Nord Psychiatr Tidsskr 42: 501–502

    Article  Google Scholar 

  • Jorgensen A, Aaes-Jorgensen T, Gravem A, Amtor KF, Dencker SJ, Rosell I, Baastrup PC, Buckhave J, Gram LF (1985) Zuclopenthixol decanoate in schizophrenia: serum levels and clinical state. Psychopharmacology 87: 364–367

    Article  PubMed  CAS  Google Scholar 

  • Larsson M, Axelsson R, Forsman A (1984) On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoate. Curr Ther Res 36: 1071–1088

    Google Scholar 

  • Marder S, Hawes EM, Putten T van, Hubbard JW, McKay G, Mintz J, May PRA, Midha KK (1986) Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate. Psychopharmacology 88: 480–483

    Article  PubMed  CAS  Google Scholar 

  • Märtensson E, Nyberg G (1989) Active metabolites in plasma and CSF - Implications for therapeutic drug monitoring. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. From molecular studies to clinical reality. Springer, Berlin Heidelberg New York London Paris Tokyo Hong Kong (Psychopharmacology series, vol 7 ), pp 257–268

    Google Scholar 

  • Mendlewicz J, Linkowski P, Alexandre J, Schoutens A (1981) Haloperidol plasma levels and clinical response in schizophrenia. In: Usdin E, Dahl SG, Gram LF, Lingjaerde O (eds) Clinical pharmacology in psychiatry -Neuroleptic and antidepressant research. Macmillan, London, pp 233–237

    Google Scholar 

  • Morel E, Lloyd KG, Dahl SG (1987) Anti-apomorphine effects of phenothiazine drug metabolites. Psychopharmacology 92: 68–72

    Article  PubMed  CAS  Google Scholar 

  • Petersen PV, Moller Nielsen I, Pedersen V, Jorgensen A, Lassen N (1977) Thioxanthenes. In: Usdin E, Forrest IS (eds) Psychotherapeutic drugs, part 2: Applications. Dekker, New York, pp 827–867

    Google Scholar 

  • Putten T van, May PRA, Jenden DJ (1981) Does a plasma level of chlorpromazine help? Psychol Med 11: 729–734

    Article  PubMed  Google Scholar 

  • Usdin E (1971) The assay of chlorpromazine and metabolites in blood, urine and other tissues. CRC Grit Rev Clin Lab Sci 2: 347–391

    Article  CAS  Google Scholar 

  • Weiner PK, Langridge RL, Blaney JM, Schaefer R, Kollman PA (1982) Electrostatic potential molecular surfaces. Proc Natl Acad Sci USA 79: 3754–3758

    Article  PubMed  CAS  Google Scholar 

  • Wiesel F-A, Alfredsson G, Ehrnebo M, Sedvall G (1980) The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. Eur J Clin Pharmacol 17: 385–391

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. S. G. Dahl
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Klinik und Poliklinik der Freien Universität Berlin, Eschenallee 3, D-1000, Berlin 19, Germany

    B. Müller-Oerlinghausen

  2. Abteilung Psychiatrie, Universitäts-Nervenklinik und Poliklinik Bonn, Sigmund-Freud-Straße 25, D-5300, Bonn-Venusberg 1, Germany

    H.-J. Möller

  3. Psychiatrische Universitätsklinik, Robert-Koch-Straße 40, D-3400, Göttingen, Germany

    E. Rüther

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Dahl, S.G. (1990). Pharmakokinetik der Neuroleptika. In: Müller-Oerlinghausen, B., Möller, HJ., Rüther, E. (eds) Thioxanthene. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75194-3_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-75194-3_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-51847-1

  • Online ISBN: 978-3-642-75194-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation